[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Biolojic Design Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100654273","phase-1-this-clinical-study-is-to-evaluate-the-safety-tolerability-pharmacokinetics-pk-pharmacodynamics-pd-and-preliminary-antitumor-activity-of-bd200-in-participants-with-advanced-or-metastatic-cancer-100654273",false,"NCT07797907","This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.","A Phase 1a\u002Fb, First-in-Human Dose Escalation and Dose Expansion Clinical Study of the Dual Targeting Trop-2 and Nectin-4 Multibody Drug Conjugate BD200 in Participants With Select Unresectable Locally Advanced or Metastatic Cancers","Inclusion Criteria:\n\n* Age 18+ years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Participant willing to provide tumor biopsies\n* Measurable disease per RECIST v1.1\n* Histologically-confirmed advanced, metastatic, or recurrent solid tumors that is not amenable to surgical resection or other approved therapeutic options\n* Satisfy requirements for prior treatments per tumor type as outlined in the protocol\n* Adequate organ function\n* Agree to contraception requirements as outlined in the protocol\n\nExclusion Criteria:\n\n* Any major surgery or traumatic injury prior to enrollment\n* Unhealed wounds from surgery or injury\n* Received other therapies within 4 weeks prior to enrollment\n* Any clinically significant chronic gastrointestinal (GI) disorder\n* Any clinically significant ascites or liver disease\n* Any clinically significant pulmonary compromise\n* Active infection at the time enrollment\n* Active autoimmune disease\n* History or active skin disease requiring frequent treatment\n* Any clinically significant corneal disorder\n* Active known second malignancy\n* Any clinically significant cardiac disease\n* Participants with tumor abutting or eroding a major vessel\n* Pregnant or lactating or planning to become pregnant\n* Known hypersensitivity to BD200 or any of its ingredients\n* Unresolved toxicities from previous anticancer therapy\n* Participation in a concurrent clinical study in the treatment period\n* Part A Only: Participant with hepatitis B virus (HBV), hepatitis virus (HCV) or human immunodeficiency virus (HIV) infection\n\nNote: Other inclusion and exclusion criteria may apply.","ALL","18 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of BD200 in adult participants with advanced solid cancers. This is an open-label study consisting of two-parts: Part A Dose Escalation and Part B Dose Expansion. At least one tumor-specific cohort will be selected in Part B Dose Expansion.",[26],"Solid Tumor (Phase I)","NOT_YET_RECRUITING","2026-08-27",{"date":30,"type":31},"2026-09-01","ACTUAL",{"date":33,"type":20},"2026-12-31",{"date":35,"type":20},"2030-12-31",{"name":37,"class":38},"Biolojic Design Ltd.","INDUSTRY",""]